Tratamiento psicofarmacológico del trastorno bipolar en América Latina

Heeren, Oscar; Carmona, Manuel Sánchez de; Vásquez, Gustavo; Córdoba, R; Forero, Jorge; Madrid, Luis; Lara, Diogo R.; Medina, Rafael; Meza, Luís

doi:10.1016/j.rpsm.2011.08.001

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asimismo, la sintomatología depresiva es mucho más frecuente entre los pacientes bipolares tipo II que tipo I (Forte et al, 2015). Por estas razones, los médicos suelen inclinarse hacia la recomendación de iniciar un tratamiento con fármacos antidepresivos más tempranamente en pacientes con TB II (Heeren et al, 2011).…”

Section: Uso De Antidepresivos En La Depresión Bipolarunclassified

Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B

Cetkovich-Bakmas¹,

Abadi²,

Camino³

et al. 2023

Vertex Rev Arg Psiquiatr

View full text Add to dashboard Cite

Este documento constituye la segunda parte B del Tercer Consenso Argentino sobre el Manejo de los Trastornos Bipolares llevada a cabo por la Asociación Argentina de Psiquiatría Biológica (AAPB). Siguiendo con el direccionamiento iniciado en el parte 2A sobre el tratamiento integral de los trastornos bipolares, esta sección se ha enfocado en sintetizar la evidencia más actualizada sobre abordajes terapéuticos para pacientes adultos. El alcance de esta sección es proporcionar recomendaciones terapéuticas para el manejo de los trastornos bipolares en adultos, (i) manía aguda, (ii) depresión bipolar, (iii) estado mixto, (iv) el suicidio en el trastorno bipolar, (v) intervenciones psicológicas. Además, el presente manuscrito aborda la evaluación y el manejo de los efectos secundarios de los tratamientos farmacoterapéuticos.

show abstract

Section: Uso De Antidepresivos En La Depresión Bipolarunclassified

Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B

Cetkovich-Bakmas¹,

Abadi²,

Camino³

et al. 2023

Vertex Rev Arg Psiquiatr

View full text Add to dashboard Cite

show abstract

“…Both valproic acid and lithium have gained popularity in Latin-American countries. Heenren et al [ 124 ] sent out a 14-item questionnaire to psychiatrists from eight Latin-American countries—Argentina, Colombia, Costa Rica, Ecuador, Mexico, Peru and Venezuela—to study their treatment preferences for patients with bipolar disorder. The authors reported that lithium and valproic acid were by far the top choices among Latin-American psychiatrists when asked about the first mood stabilizer of choice for a patient with bipolar disorder and that with a manic episode, 50% and 41.6%, respectively [ 124 ].…”

Section: Valproate As Mood Stabilizermentioning

confidence: 99%

A History of the Pharmacological Treatment of Bipolar Disorder

López-Muñoz

Shen

D’Ocón

et al. 2018

IJMS

119

View full text Add to dashboard Cite

In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade’s experiments with lithium and the beginning of the so-called “Psychopharmacological Revolution” in the 1950s. We also describe the clinical studies and development processes, enabling the therapeutic introduction of pharmacological agents currently available for the treatment of bipolar disorder in its different phases and manifestations. Those drugs include lithium salts, valproic acid, carbamazepine, new antiepileptic drugs, basically lamotrigine and atypical antipsychotic agents (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, asenapine, cariprazine and lurasidone). Finally, the socio-sanitary implications derived from the clinical introduction of these drugs are also discussed.

show abstract

Characteristics of bipolar disorder patients given antidepressants

Lorenzo¹,

Vázquez²,

Zaratiegui³

et al. 2012

Human Psychopharmacology

View full text Add to dashboard Cite

Evidence concerning efficacy of antidepressants in bipolar disorder remains inconsistent and inconclusive. As the appropriate clinical use for such patients remains unclear, we characterized outpatients with bipolar disorders who were or were not treated with antidepressants. Clinical data were collected systematically from consecutive outpatients in 11 participating Argentine mood-disorder clinics in 2007-2008. Diagnoses met DSM-IV criteria, supported by structured interviews based on the MINI-500. Of 338 outpatients diagnosed with bipolar I (45.0%), II (29.3%), or not-otherwise-specified (NOS) (25.7%) disorder, 128 (37.9%) received antidepressants. Subjects given antidepressants or not did not differ significantly by presence or severity of current depression or being suicidal but were more likely to be women. Bipolar I disorder patients were three times less likely than types II or NOS to receive an antidepressant, with or without a mood-stabilizer or antimanic agent. Despite inconclusive evidence for efficacy and safety of antidepressants in various phases of bipolar disorders, 37.9% of such patients were receiving an antidepressant in 11 Argentine outpatient clinics. Antidepressant treatment was least likely with type I disorder and was independent of current depression and not associated with more use of mood-stabilizing or antimanic agents.

show abstract

Tratamiento psicofarmacológico del trastorno bipolar en América Latina

Cited by 7 publications

References 31 publications

Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B

Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B

A History of the Pharmacological Treatment of Bipolar Disorder

Characteristics of bipolar disorder patients given antidepressants

Contact Info

Product

Resources

About